Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
It is a new therapeutic option for adults with Philadelphia chromosome‑positive chronic myeloid leukaemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors
Findings from the Dutch Pharmacology Oncology Group - Therapeutic Drug Monitoring study show that pharmacokinetically guided dose-adjustments of oral targeted therapies are feasible in clinical practice
Findings from the PRO-TECT (Alliance AFT-39) cluster randomised study should be interpreted provisionally pending results of the primary outcome of overall survival
Vegzelma is highly similar to the reference product Avastin, which was authorised in the EU in January 2005
Very suboptimal vaccine responses generated by subset of patients with non-small cell lung cancer cannot be explained solely by older age and type of vaccine
Safety and efficacy were evaluated in BRF117019, NCI-MATCH, CTMT212X2101, and supported by results in COMBI-d, COMBI-v, and BRF113928 studies
Findings of 4 years follow-up from the CheckMate 142 study
Final survival results in EORTC 26951 and RTOG 9402 phase III studies with addition of procarbazine, lomustine, and vincristine to radiotherapy
New indication concerns the adjuvant treatment of adult patients with germline BRCA1/2 mutations who have HER2-negative, high risk early breast cancer
Findings from a population-level retrospective cohort study
Evidence for efficacy is based on the results from the ELARA study
The risk of ocular toxicity, including risk of severe visual loss and need for monitoring in paediatric patients treated with crizotinib
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
